|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ali AY, Farrand L, Kim JY, Byun S, Suh JY,
Lee HJ and Tsang BK: Molecular determinants of ovarian cancer
chemoresistance: New insights into an old conundrum. Ann NY Acad
Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Limtrakul P, Pitchakarn P and Suzuki S:
Kuguacin J, a Triterpenoid from Momordica charantia Linn: A
Comprehensive Review of Anticarcinogenic Properties. INTECH Open
Access Publisher; View
Article : Google Scholar : 2013
|
|
4
|
Al Rawahi T, Lopes AD, Bristow RE, Bryant
A, Elattar A, Chattopadhyay S and Galaal K: Surgical cytoreduction
for recurrent epithelial ovarian cancer. Cochrane Database Syst
Rev. Feb;28(2): CD008765 View Article : Google Scholar : 2013.
|
|
5
|
Wang V, Li C, Lin M, Welch W, Bell D, Wong
YF, Berkowitz R, Mok SC and Bandera CA: Ovarian cancer is a
heterogeneous disease. Cancer Genet Cytogenet. 161:170–173. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cragg DJ, Kingston GM and Newman DG:
Anticancer Agents from Natural Products. CRC Press; 2011,
View Article : Google Scholar
|
|
7
|
Butler MS, Robertson AA and Cooper MA:
Natural product and natural product derived drugs in clinical
trials. Nat Prod Rep. 31:1612–1661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs from 1981 to 2014. J Nat Prod. 79:629–661.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goldbohm RA, Hertog MG, Brants HA, van
Poppel G and van den Brandt PA: Consumption of black tea and cancer
risk: A prospective cohort study. J Natl Cancer Inst. 88:93–100.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cassidy A, Huang T, Rice MS, Rimm EB and
Tworoger SS: Intake of dietary flavonoids and risk of epithelial
ovarian cancer. Am J Clin Nutr. 100:1344–1351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Finger A: In vitro studies on the effect
of polyphenol oxidase and peroxidase on the formation of
polyphenolic black tea constituents. J Sci Food Agric. 66:293–305.
1994. View Article : Google Scholar
|
|
12
|
Yang GY, Liu Z, Seril DN, Liao J, Ding W,
Kim S, Bondoc F and Yang CS: Black tea constituents, theaflavins,
inhibit 4- (methylnitrosamino)-1- (3-pyridyl)-1-butanone
(NNK)-induced lung tumorigenesis in A/J mice. Carcinogenesis.
18:2361–2365. 1997. View Article : Google Scholar
|
|
13
|
Lu J, Ho C-T, Ghai G and Chen KY:
Differential effects of theaflavin monogallates on cell growth,
apoptosis, and Cox-2 gene expression in cancerous versus normal
cells. Cancer Res. 60:6465–6471. 2000.PubMed/NCBI
|
|
14
|
Hibasami H, Komiya T, Achiwa Y, Ohnishi K,
Kojima T, Nakanishi K, Sugimoto Y, Hasegawa M, Akatsuka R and Hara
Y: Black tea theaflavins induce programmed cell death in cultured
human stomach cancer cells. Int J Mol Med. 1:725–727.
1998.PubMed/NCBI
|
|
15
|
Lahiry L, Saha B, Chakraborty J, Adhikary
A, Mohanty S, Hossain DM, Banerjee S, Das K, Sa G and Das T:
Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce
apoptosis in p53-mutated human breast cancer cells. Carcinogenesis.
31:259–268. 2010. View Article : Google Scholar
|
|
16
|
Tu Y, Kim E, Gao Y, Rankin GO, Li B and
Chen YC: Theaflavin-3, 3′-digallate induces apoptosis and G2 cell
cycle arrest through the Akt/MDM2/p53 pathway in
cisplatin-resistant ovarian cancer A2780/CP70 cells. Int J Oncol.
48:2657–2665. 2016.PubMed/NCBI
|
|
17
|
Gao Y, Rankin GO, Tu Y and Chen YC:
Theaflavin-3, 3′-digallate decreases human ovarian carcinoma
OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not
via MAPK pathways. Int J Oncol. 48:281–292. 2016. View Article : Google Scholar
|
|
18
|
Gao Y, Rankin GO, Tu Y and Chen YC:
Inhibitory Effects of the Four Main Theaflavin Derivatives Found in
Black Tea on Ovarian Cancer Cells. Anticancer Res. 36:643–651.
2016.PubMed/NCBI
|
|
19
|
Xu Y, Jin Y, Wu Y and Tu Y: Isolation and
purification of four individual theaflavins using semi-preparative
high performance liquid chromatography. J Liq Chromatogr Relat
Technol. 33:1791–1801. 2010. View Article : Google Scholar
|
|
20
|
Levine AJ: p53 the cellular gatekeeper for
growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lakin ND and Jackson SP: Regulation of p53
in response to DNA damage. Oncogene. 18:7644–7655. 1999. View Article : Google Scholar
|
|
22
|
Burma S, Chen BP, Murphy M, Kurimasa A and
Chen DJ: ATM phosphorylates histone H2AX in response to DNA
double-strand breaks. J Biol Chem. 276:42462–42467. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tibbetts RS, Brumbaugh KM, Williams JM,
Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C and Abraham RT: A
role for ATR in the DNA damage-induced phosphorylation of p53.
Genes Dev. 13:152–157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gottlieb TM, Leal JFM, Seger R, Taya Y and
Oren M: Cross-talk between Akt, p53 and Mdm2: Possible implications
for the regulation of apoptosis. Oncogene. 21:1299–1303. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Franke TF, Kaplan DR and Cantley LC: PI3K:
Downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Franke TF, Yang S-I, Chan TO, Datta K,
Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein
kinase encoded by the Akt proto-oncogene is a target of the PDGF-
activated phosphatidylinositol 3-kinase. Cell. 81:727–736. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and
subcellular localization. Genes Dev. 12:3499–3511. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu GS: The functional interactions between
the p53 and MAPK signaling pathways. Cancer Biol Ther. 3:156–161.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Blagosklonny MV: Overcoming limitations of
natural anticancer drugs by combining with artificial agents.
Trends Pharmacol Sci. 26:77–81. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hassan M, Watari H, AbuAlmaaty A, Ohba Y
and Sakuragi N: Apoptosis and molecular targeting therapy in
cancer. BioMed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 7:72015. View Article : Google Scholar
|
|
33
|
Knaapen M, De Bie M, Muhring J and Kockx
M: Cleaved PARP as a marker for apoptosis in tissue sections.
Promega Notes. 72:71999.
|
|
34
|
Los M, Mozoluk M, Ferrari D, Stepczynska
A, Stroh C, Renz A, Herceg Z, Wang ZQ and Schulze-Osthoff K:
Activation and caspase-mediated inhibition of PARP: A molecular
switch between fibroblast necrosis and apoptosis in death receptor
signaling. Mol Biol Cell. 13:978–988. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morales J, Li L, Fattah FJ, Dong Y, Bey
EA, Patel M, Gao J and Boothman DA: Review of poly (ADP-Ribose)
polymerase (PARP) mechanisms of action and rationale for targeting
in cancer and other diseases. Crit Rev Eukaryot Gene Expr.
24:15–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chow A: Cell cycle control by oncogenes
and tumor suppressors: Driving the transformation of normal cells
into cancerous cells. Nature Education. 3:72010.
|
|
37
|
Sherr CJ and Bartek J: Cell cycle-targeted
cancer therapies. Annu Rev Cancer Biol. 1:41–57. 2017. View Article : Google Scholar
|
|
38
|
Zhang G, Miura Y and Yagasaki K: Induction
of apoptosis and cell cycle arrest in cancer cells by in vivo
metabolites of teas. Nutr Cancer. 38:265–273. 2000. View Article : Google Scholar
|
|
39
|
Prasad S, Kaur J, Roy P, Kalra N and
Shukla Y: Theaflavins induce G2/M arrest by modulating expression
of p21waf1/cip1, cdc25C and cyclin B in human prostate
carcinoma PC-3 cells. Life Sci. 81:1323–1331. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kawabe T: G2 checkpoint abrogators as
anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
|
|
41
|
Waldman T, Kinzler KW and Vogelstein B:
p21 is necessary for the p53-mediated G1 arrest in human cancer
cells. Cancer Res. 55:5187–5190. 1995.PubMed/NCBI
|
|
42
|
Yu W, Park S-K, Jia L, Tiwary R, Scott WW,
Li J, Wang P, Simmons-Menchaca M, Sanders BG and Kline K:
RRR-γ-tocopherol induces human breast cancer cells to undergo
apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling.
Cancer Lett. 259:165–176. 2008. View Article : Google Scholar
|
|
43
|
Ozaki T and Nakagawara A: Role of p53 in
cell death and human cancers. Cancers (Basel). 3:994–1013. 2011.
View Article : Google Scholar
|
|
44
|
Khoo KH, Verma CS and Lane DP: Drugging
the p53 pathway: Understanding the route to clinical efficacy. Nat
Rev Drug Discov. 13:217–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Brown R, Clugston C, Burns P, Edlin A,
Vasey P, Vojtĕsek B and Kaye SB: Increased accumulation of p53
protein in cisplatin-resistant ovarian cell lines. Int J Cancer.
55:678–684. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lahiry L, Saha B, Chakraborty J,
Bhattacharyya S, Chattopadhyay S, Banerjee S, Choudhuri T, Mandal
D, Bhattacharyya A, Sa G, et al: Contribution of p53-mediated Bax
transactivation in theaflavin- induced mammary epithelial carcinoma
cell apoptosis. Apoptosis. 13:771–781. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kalra N, Seth K, Prasad S, Singh M, Pant
AB and Shukla Y: Theaflavins induced apoptosis of LNCaP cells is
mediated through induction of p53 down-regulation of NF-kappa B and
mitogen-activated protein kinases pathways. Life Sci. 80:2137–2146.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Meek DW: The p53 response to DNA damage.
DNA Repair (Amst). 3:1049–1056. 2004. View Article : Google Scholar
|
|
49
|
Lee JH and Paull TT: Activation and
regulation of ATM kinase activity in response to DNA double-strand
breaks. Oncogene. 26:7741–7748. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhao H and Piwnica-Worms H: ATR-mediated
checkpoint pathways regulate phosphorylation and activation of
human Chk1. Mol Cell Biol. 21:4129–4139. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Matsuoka S, Rotman G, Ogawa A, Shiloh Y,
Tamai K and Elledge SJ: Ataxia telangiectasia-mutated
phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA.
97:10389–10394. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Melchionna R, Chen X-B, Blasina A and
McGowan CH: Threonine 68 is required for radiation-induced
phosphorylation and activation of Cds1. Nat Cell Biol. 2:762–765.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yuan J, Adamski R and Chen J: Focus on
histone variant H2AX: To be or not to be. FEBS Lett. 584:3717–3724.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shieh S-Y, Ikeda M, Taya Y and Prives C:
DNA damage-induced phosphorylation of p53 alleviates inhibition by
MDM2. Cell. 91:325–334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sahu RP, Batra S and Srivastava SK:
Activation of ATM/Chk1 by curcumin causes cell cycle arrest and
apoptosis in human pancreatic cancer cells. Br J Cancer.
100:1425–1433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee H, Kim Y, Jeong JH, Ryu J-H and Kim
W-Y: ATM/CHK/p53 pathway dependent chemopreventive and therapeutic
activity on lung cancer by pterostilbene. PloS One.
11:e01623352016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Crowell JA, Steele VE and Fay JR:
Targeting the AKT protein kinase for cancer chemoprevention. Mol
Cancer Ther. 6:2139–2148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Abraham AG and O'Neill E:
PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans.
42:798–803. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim CW, Lu JN, Go S-I, Jung JH, Yi SM,
Jeong JH, Hah YS, Han MS, Park JW, Lee WS, et al: p53 restoration
can overcome cisplatin resistance through inhibition of Akt as well
as induction of Bax. Int J Oncol. 43:1495–1502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cheng T-L, Symons M and Jou T-S:
Regulation of anoikis by Cdc42 and Rac1. Exp Cell Res. 295:497–511.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hong B, Li H, Zhang M, Xu J, Lu Y, Zheng
Y, Qian J, Chang JT, Yang J and Yi Q: p38 MAPK inhibits breast
cancer metastasis through regulation of stromal expansion. Int J
Cancer. 136:34–43. 2015. View Article : Google Scholar
|
|
66
|
Kohno M and Pouyssegur J: Targeting the
ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Dong Z, Ma W, Huang C and Yang CS:
Inhibition of tumor promoter-induced activator protein 1 activation
and cell transformation by tea polyphenols, (−)-epigallocatechin
gallate, and theaflavins. Cancer Res. 57:4414–4419. 1997.PubMed/NCBI
|
|
68
|
Vivas-Mejia P, Benito JM, Fernandez A, Han
H-D, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey
MS, Nick AM, et al: JNK-1 inhibition leads to antitumor activity in
ovarian cancer. Clin Cancer Res. 16:184–194. 2010. View Article : Google Scholar
|
|
69
|
Kitanaka C, Sato A and Okada M: JNK
signaling in the control of the tumor-initiating capacity
associated with cancer stem cells. Genes Cancer. 4:388–396. 2013.
View Article : Google Scholar : PubMed/NCBI
|
